Table 3

Factors associated with availability (primary outcome) and administration of oxytocin (secondary outcome)

Oxytocin availabilityOxytocin administration for prevention of postpartum haemorrhage
Crude OR
(95% CI)
(n=2257)
Adjusted OR*
(95% CI)
(n=2257)
Crude OR
(95% CI)
(n=2343)
Adjusted OR
(95% CI)
(n=2343)
First-phase follow-up7.29
(1.48to35.84)
8.41
(1.50to47.30)
1.43
(0.79 to 2.62)
1.63
(0.83 to 3.21)
Country
 BelizePredicts success perfectly†Predicts success perfectly0.52
(0.13 to 2.12)
0.44
(0.11 to 1.71)
 Guatemala1111
 Honduras1.70
(0.18 to 16.46)
2.24
(0.27 to 18.24)
2.71
(1.02to7.22)
2.96
(1.00to8.76)
 Mexico0.67
(0.14 to 3.10)
0.51
(0.11 to 2.46)
0.57
(0.25 to 1.31)
0.57
(0.24 to 1.37)
 Nicaragua2.22
(0.23 to 21.71)
2.01
(0.19 to 20.92)
1.00
(0.38 to 2.62)
0.95
(0.35 to 2.54)
 Panama3.43
(0.36 to 33.05)
3.83
(0.36 to 41.22)
1.04
(0.41 to 2.66)
1.03
(0.40 to 2.61)
Comprehensive-level facility1.00
(0.24 to 4.15)
1.29
(0.31 to 5.31)
0.92
(0.47 to 1.81)
0.96
(0.46 to 2.00)
Relevant training‡1.49
(0.71 to 3.13)
1.08
(0.44 to 2.67)
Oxytocin availability§2.01
(0.92 to 4.39)
1.45
(0.66 to 3.19)
  • All models clustered at health facility level.

  • *Adjusted for first-phase follow-up, country and comprehensive-level facility. Relevant training and oxytocin availability not included (not applicable).

  • †Belize attained availability of oxytocin at all times (regression for this binary variable not possible).

  • ‡Within last year, includes routine labour care, basic emergency obstetrical care and maternal complications.

  • §Day of survey visit.